Long-Term Results of Post-Prostatectomy Radiotherapy

In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

The newly approved supplemental new drug application for Illuccix by the FDA will enable patients with prostate cancer to be identified and selected for radioligand therapy.

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Geynisman, MD, discussed with participants the choice of hormonal therapy for metastatic prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan Y. Yu, MD, discussed with participants role of prostate-specific membrane antigen in metastatic castration-resistant prostate cancer.